Published 1987 | Version v1
Miscellaneous Open

131I Metaiodobenzylguanidine (131I MIBG) kinetics in a carcinoid tumor

Description

The 131I-MIBG kinetics was studied in vivo in patients with carcinoid tumors and liver metastases. Activity curve analysis showed that the maximum uptake of 131I-MIBG in a carcinoid tumor occurred after 48 hours, while its biological half time was of 8 days and a half. Although more data are necessary to understand a significant variation in 131I-MIBG kinetics between the different kinds of APUD neoplasms, it is thought that a dynamic-funtional study allowing the evaluation of the different biological half-time, could be helpful for the selection of these neoplasms, which could be treated with 131I-MIBG. Radiation doses required for the treatment are also estimated. (M.E.L.)

Abstract (Spanish)

Se estudio in vivo la cinetica del 131I-MIBG en pacientes con metastasis hepatica en casos que padecian tumores cancerosos. El analisis de la curva de actividad demostro que la fijacion maxima de 131I-MIBG en un tumor canceroso ocurrio a 48 hs, mientras que el periodo biologico de semidesintegracion fue de 8 dias y medio. A pesar de ser necesarios mas datos para entender si hay una variacion significativa en la cinetica del 131I-MIBG entre las diferentes clases de neoplasmas APUD, se penso que un estudio dinamico-funcional permitiendo la evaluacion de los diferentes tiempos medio biologicos, podria ser util para la seleccion de dichos neoplasmas, los cuales podrian ser tratados con 131I-MIBG y establecer la dosis de radiacion requerida por el tratamiento. (M.E.L.)

Files

20084948.pdf

Files (213.7 kB)

Name Size Download all
md5:0ed552864402b887de287e81fac8020d
213.7 kB Preview Download

Additional details

Publishing Information

Imprint Title
Progress in radiopharmacology
Imprint Pagination
212 p.
Journal Page Range
p. 64-74.
Report number
INIS-mf--11544

Conference

Title
5. International symposium on radiopharmacology.
Dates
29-31 Oct 1986.
Place
Buenos Aires (Argentina).